Guardant Health Dirección

Dirección controles de criterios 4/4

El CEO de Guardant Health es Helmy Eltoukhy , nombrado en Jan 2013, tiene una permanencia de 11.83 años. compensación anual total es $11.59K, compuesta por 0.01% salario y 100% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.13% de las acciones de la empresa, por valor de €78.34M. La antigüedad media del equipo directivo y de la junta directiva es de 3.5 años y 3.2 años, respectivamente.

Información clave

Helmy Eltoukhy

Chief Executive Officer (CEO)

US$11.6k

Compensación total

Porcentaje del salario del CEO	0.009%
Permanencia del CEO	11.8yrs
Participación del CEO	2.1%
Permanencia media de la dirección	3.5yrs
Promedio de permanencia en la Junta Directiva	3.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Helmy Eltoukhy en comparación con los beneficios de Guardant Health?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-US$512m
Jun 30 2024	n/a	n/a	-US$491m
Mar 31 2024	n/a	n/a	-US$461m
Dec 31 2023	US$12k	US$1	-US$479m
Sep 30 2023	n/a	n/a	-US$432m
Jun 30 2023	n/a	n/a	-US$508m
Mar 31 2023	n/a	n/a	-US$665m
Dec 31 2022	US$12k	US$1	-US$655m
Sep 30 2022	n/a	n/a	-US$606m
Jun 30 2022	n/a	n/a	-US$551m
Mar 31 2022	n/a	n/a	-US$419m
Dec 31 2021	US$14k	US$1	-US$406m
Sep 30 2021	n/a	n/a	-US$409m
Jun 30 2021	n/a	n/a	-US$379m
Mar 31 2021	n/a	n/a	-US$336m
Dec 31 2020	US$114m	US$210k	-US$254m
Sep 30 2020	n/a	n/a	-US$185m
Jun 30 2020	n/a	n/a	-US$120m
Mar 31 2020	n/a	n/a	-US$77m
Dec 31 2019	US$915k	US$500k	-US$76m
Sep 30 2019	n/a	n/a	-US$76m
Jun 30 2019	n/a	n/a	-US$87m
Mar 31 2019	n/a	n/a	-US$97m
Dec 31 2018	US$818k	US$480k	-US$85m
Sep 30 2018	n/a	n/a	-US$75m
Jun 30 2018	n/a	n/a	-US$84m
Mar 31 2018	n/a	n/a	-US$83m
Dec 31 2017	US$4m	US$460k	-US$89m

Compensación vs. Mercado: La compensación total de Helmy($USD11.59K) está por debajo de la media de empresas de tamaño similar en el mercado German ($USD1.90M).

Compensación vs. Ingresos: La compensación de Helmy ha sido consistente con los resultados de la empresa en el último año.

CEO

Helmy Eltoukhy (45 yo)

11.8yrs

Permanencia

US$11,591

Compensación

Dr. Helmy Eltoukhy, Ph D., is Partner of Green Sands Equity Incorporated. He is Equity Partner and Advisor of Transform VC.Dr. Eltoukhy has been the Chairman of the Board of Directors of Guardant Health,...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Helmy Eltoukhy	Co-Founder	11.8yrs	US$11.59k	2.13% € 78.3m
AmirAli Talasaz	Co-CEO & Director	3.3yrs	US$26.42k	2.2% € 81.0m
Michael Bell	Chief Financial Officer	3.8yrs	US$4.12m	0.019% € 716.4k
Darya Chudova	Chief Technology Officer	no data	US$4.76m	0.044% € 1.6m
Craig Eagle	Chief Medical Officer	3.5yrs	US$3.49m	0.019% € 692.1k
Christopher Freeman	Chief Commercial Officer	3.4yrs	US$3.52m	0.025% € 935.8k
Kumud Kalia	Chief Information Officer	4.8yrs	sin datos	0.014% € 527.8k
Zarak Khurshid	Vice President of Investor Relations	no data	sin datos	sin datos
John Saia	Chief Legal Officer & Corporate Secretary	4.5yrs	US$6.02m	0.027% € 980.3k
Jennifer Higgins	Senior Vice President of Public Affairs	no data	sin datos	sin datos
Stephen Murphy	Senior Vice President of Marketing	less than a year	sin datos	sin datos
Terilyn Monroe	Chief People Officer	less than a year	sin datos	sin datos

3.5yrs

Permanencia media

51yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 5GH se considera experimentado (3.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Helmy Eltoukhy	Co-Founder	11.8yrs	US$11.59k	2.13% € 78.3m
AmirAli Talasaz	Co-CEO & Director	11.8yrs	US$26.42k	2.2% € 81.0m
Myrtle Potter	Independent Director	3.1yrs	US$425.21k	0.011% € 406.2k
Ian T. Clark	Lead Independent Director	7.8yrs	US$470.21k	0.0068% € 251.1k
Roberto Mignone	Director	less than a year	sin datos	sin datos
Steve Krognes	Independent Director	2.4yrs	US$425.21k	0.0080% € 294.8k
Musa Tariq	Independent Director	1.7yrs	US$725.30k	0.0040% € 148.5k
Vijaya Gadde	Independent Director	4.4yrs	US$425.21k	0.014% € 524.9k
Meghan Joyce	Independent Director	3.3yrs	US$425.21k	0.0062% € 227.5k
Manuel Medina	Director	less than a year	sin datos	sin datos

3.2yrs

Permanencia media

50.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 5GH se considera experimentada (3.2 años de antigüedad promedio).

Guardant Health Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director

High number of new directors

Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors

Guardant Health, Inc., Annual General Meeting, Jun 12, 2024

Guardant Health, Inc. Announces Executive Changes

Guardant Health, Inc. Announces Management Changes

Recent updates

Now 22% undervalued

Third quarter 2024 earnings released: US$0.88 loss per share (vs US$0.73 loss in 3Q 2023)

Guardant Health, Inc. Revises Revenue Guidance for the Year 2024

Guardant Health, Inc. Appoints Roberto Mignone. as Class I Director

Guardant Health, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Guardant Health, Inc. has filed a Follow-on Equity Offering in the amount of $400 million.

Second quarter 2024 earnings released: US$0.84 loss per share (vs US$0.67 loss in 2Q 2023)

Guardant Health, Inc. Raises Earnings Guidance for the Full Year of 2024

New major risk - Share price stability

Guardant Health, Inc.'s FDA-Appoints Shield™? Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

High number of new directors

Guardant Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Guardant Health, Inc. Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-In-Class Performance

Guardant Health, Inc. Announces the Appointment of Dr. Manuel Hidalgo Medina to Board of Directors

Guardant Health Introduces New Guardant360 Tissuenext Test with Nearly 500 Biomarkers to Identify More Treatment Options for Patients with Advanced Cancer

Guardant Health, Inc. Announces FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option

Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024

First quarter 2024 earnings released: US$0.94 loss per share (vs US$1.30 loss in 1Q 2023)

Guardant Health, Inc., Annual General Meeting, Jun 12, 2024

Guardant Health, Inc. to Report Q1, 2024 Results on May 09, 2024

New major risk - Share price stability

Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting

Guardant Health, Inc. Announces Results from the ECLIPSE Study Showing the Effectiveness of Its Shield Blood Test for Detecting Colorectal Cancer

Full year 2023 earnings released: US$4.28 loss per share (vs US$6.41 loss in FY 2022)

Guardant Health, Inc. Provides Earnings Guidance for the Year 2024

Guardant Health, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Guardant Health, Inc. Announces Executive Changes

Guardant Health, Inc. Announces Tentative Date of FDA Advisory Panel Review of Shield(TM) Blood Test

Guardant Health, Inc. to Appeal Federal District Court Verdict

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$1.58 loss in 3Q 2022)

Guardant Health, Inc. Provides Revenue Guidance for Full Year 2023

Guardant Health, Inc. Announces Initial Results from the PEGASUS Trial

Guardant Health, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Now 20% undervalued after recent price drop

Guardant Health, Inc. Receives Coverage for Guardant Reveal from Geisinger Health Plan

Guardant Health, Inc. Receives Regulatory Approval in Japan for Guardant360®? CDx as Companion Diagnostic to ENHERTU®? for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations

Second quarter 2023 earnings released: US$0.67 loss per share (vs US$2.25 loss in 2Q 2022)

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Guardant Health, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Guardant Health, Inc. Announces Reimbursement Approval of Guardant360 CDx Liquid Biopsy Test in Japan

Guardant Health, Inc.(NasdaqGS:GH) dropped from Russell 1000 Dynamic Index

Guardant Health, Inc. has completed a Follow-on Equity Offering in the amount of $350 million.

Guardant Health, Inc. Revises Revenue Guidance for the Full Year 2023

First quarter 2023 earnings released: US$1.30 loss per share (vs US$1.21 loss in 1Q 2022)

Guardant Health, Inc. Announces Management Changes

High number of new directors

Co-CEO & Director recently bought €2.3m worth of stock

Chief Information Officer recently sold €182k worth of stock

Full year 2022 earnings released: US$6.41 loss per share (vs US$4.00 loss in FY 2021)

Guardant Health, Inc. Initiates New Study to Examine the Impact of Shield Blood Test to Increase Screening Compliance for Colorectal Cancer

Guardant Health, Inc. Receives Coverage from UnitedHealthcare for Guardant360® CDx Blood Test as Companion Diagnostic in Advanced Lung and Breast Cancer

Guardant Health, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Guardant Health Introduces Guardant Galaxytm Suite of Advanced Ai Analytics to Enhance Its Portfolio of Cancer Tests and Accelerate Biomarker Discovery

Guardant Health, Inc. Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Menarini Group’S ORSERDU for Treatment of Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

Guardant Health and the Royal Marsden NHS Foundation Trust Partner on Highly Anticipated TRACC Part C Trial to Use Guardant Reveal(Tm) Blood Test to Help Guide Treatment Decisions in Colorectal Cancer

Guardant Health, Inc. to Showcase New Data at ASCO GI 2023 Demonstrating Utility of its Blood Tests for Patients with Gastrointestinal Cancers

Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Guardant Health, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Guardant Health, Inc. and Susan G. Komen(R) Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit from Additional Monitoring or Therapy

Guardant Health Announces Positive Results from Pivotal ECLIPSE Study Evaluating A Blood Test for the Detection of Colorectal Cancer

Chief Information Officer recently sold €156k worth of stock

Third quarter 2022 earnings released: US$1.58 loss per share (vs US$1.06 loss in 3Q 2021)

Guardant Health, Inc. Provides Earnings Guidance for the Full Year 2022

Guardant Health, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Guardant Health Introduces GuardantINFINITY Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

Guardant Health, Inc. to Showcase New Data At ESMO 2022 Demonstrating Utility of Its Portfolio of Blood Tests for Advanced-Stage Cancer Patients

Senior Vice President of People recently sold €212k worth of stock

Guardant Health, Inc. Receives FDA Approval for Guardant360® Cdx as Companion Diagnostic for Daiichi Sankyo and Astrazeneca’S Enhertu® for Treatment of Nsclc Patients with Activating Her2 Mutations